Latest & greatest articles for alzheimer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alzheimer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alzheimer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Alzheimer’s disease

Alzheimer’s disease is a chronic neurodegenerative disease responsible for the majority of cases of dementia. This progressive disease disrupts memory and thinking due to an accumulation of plaques and tangles in the brain. As the disease progresses, these get progressively worse.

What causes Alzheimer’s diseases is poorly understood, although there is a strong genetic component which could account for the majority (~70%) of the risk. Other risk factors have been identified, such as depression, head injuries and hypertension. Alzheimer’s disease is typically a disease of older people.

Although Alzheimer’s disease cannot currently be cured but it can be managed. With cholinesterase inhibitors being a common intervention as well as memantine (an NMDA receptor antagonist) and psychosocial interventions.

Trip has an extensive collection of research evidence and articles relating to Alzheimer’s disease including clinical guidelines, systematic reviews, synopses, clinical trials and case reports.

Top results for alzheimer

1. Treatment of epilepsy for people with Alzheimer's disease.

Treatment of epilepsy for people with Alzheimer's disease. BACKGROUND: Any type of seizure can be observed in Alzheimer's disease (AD). Antiepileptic drugs seem to prevent the recurrence of epileptic seizures in most people with AD. There are pharmacological and non-pharmacological treatments for epilepsy in people with AD. There are no current systematic reviews to evaluate the efficacy and tolerability of these treatments; this review aims to review those different modalities

Cochrane2018

2. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial 30248105 2018 11 14 1549-1676 15 9 2018 Sep PLoS medicine PLoS Med. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. e1002660 10.1371/journal.pmed.1002660 This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine (...) . Nilvadipine, licensed to treat hypertension, reduces amyloid production, increases regional cerebral blood flow, and has demonstrated anti-inflammatory and anti-tau activity in preclinical studies, properties that could have disease-modifying effects for Alzheimer disease. We aimed to determine if nilvadipine was effective in slowing cognitive decline in subjects with mild to moderate Alzheimer disease. NILVAD was an 18-month, randomised, placebo-controlled, double-blind trial that randomised participants

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

3. Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive

Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Signal - Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Dissemination Centre Discover Portal NIHR DC Discover Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Published on 11 December (...) 2015 This follow up study examined whether the drugs donepezil or memantine affected the chance that people with Alzheimer’s disease could continue to live in the community, rather than move permanently to a nursing home. One or both of the drugs was taken for a year and then participants could have any treatment thereafter. The study found that stopping donepezil doubled the risk of going into a nursing home up to a year afterwards, compared with continuing to take donepezil. However

NIHR Dissemination Centre2018

4. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. Importance: The positron emission tomography (PET) tracer [18F]flortaucipir allows in vivo quantification of paired helical filament tau, a core neuropathological feature of Alzheimer disease (AD), but its diagnostic utility is unclear. Objective: To examine the discriminative accuracy of [18F]flortaucipir for AD vs non-AD neurodegenerative disorders. Design

JAMA2018

5. Alzheimer's dementia

Alzheimer's dementia Alzheimer's dementia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Alzheimer's dementia Last reviewed: August 2018 Last updated: September 2018 Summary Chronic, progressive neurodegenerative disorder characterised by a global, non-reversible impairment in cerebral functioning. Characterised by memory loss, loss of social and occupational functioning, diminished executive function, speech (...) support groups are beneficial to caregivers and should be considered, where available. Definition Alzheimer's disease (AD) is a chronic neurodegenerative disease with an insidious onset and progressive but slow decline. AD is the most common type of dementia. Grossman H, Bergmann C, Parker S. Dementia: a brief review. Mt Sinai J Med. 2006 Nov;73(7):985-92. http://www.ncbi.nlm.nih.gov/pubmed/17195884?tool=bestpractice.com Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population

BMJ Best Practice2018

6. Alzheimer?s disease

Alzheimer?s disease Top results for alzheimer's disease - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for alzheimer's disease The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

7. Alzheimer's disease

Alzheimer's disease Autosynthesis - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing

Trip Evidence Maps2018

8. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis

Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis 29790638 2018 06 19 1463-1326 2018 May 23 Diabetes, obesity & metabolism Diabetes Obes Metab Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis. 10.1111/dom.13373 This study (registered with PROSPERO, CRD42018085967 (...) ) compares the efficacy (i.e. pro-cognitive effects) and acceptability of antidiabetic agents for Alzheimer's disease (AD) and mild cognitive impairment (MCI). Cochrane Library (CENTRAL), PubMed/MEDLINE, EMBASE and PsycINFO were searched from inception to January 15, 2018 for randomized controlled trials comparing antidiabetic agents with placebo and/or another active antidiabetic agent for the treatment of AD or MCI. Nineteen eligible studies (n = 4855) evaluating the effects of 6 different antidiabetic

EvidenceUpdates2018

9. Drugs for Alzheimer's disease: finally delisted in France!

Drugs for Alzheimer's disease: finally delisted in France! Prescrire IN ENGLISH - Spotlight ''Drugs for Alzheimer's disease: finally delisted in France!'', 15 June 2018 {1} {1} {1} | | > > > Drugs for Alzheimer's disease: finally delisted in France! Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Drugs for Alzheimer's disease: finally delisted (...) in France! The drugs available in mid-2018 for Alzheimer's disease have only minimal and transient efficacy. They have disproportionate, serious and sometimes fatal adverse effects. It is better to avoid them and to focus instead on reorganising the patient's daily life, keeping him or her active, and providing support and help for caregivers and family members. "The drugs available in early 2018 for Alzheimer's disease have only minimal and transient efficacy. They are also difficult to use because

Prescrire2018

10. Donepezil for dementia due to Alzheimer's disease.

Donepezil for dementia due to Alzheimer's disease. BACKGROUND: Alzheimer's disease is the most common cause of dementia in older people. One approach to symptomatic treatment of Alzheimer's disease is to enhance cholinergic neurotransmission in the brain by blocking the action of the enzyme responsible for the breakdown of the neurotransmitter acetylcholine. This can be done by a group of drugs known as cholinesterase inhibitors. Donepezil is a cholinesterase inhibitor.This review is an updated (...) version of a review first published in 1998. OBJECTIVES: To assess the clinical efficacy and safety of donepezil in people with mild, moderate or severe dementia due to Alzheimer's disease; to compare the efficacy and safety of different doses of donepezil; and to assess the effect of donepezil on healthcare resource use and costs. SEARCH METHODS: We searched Cochrane Dementia and Cognitive Improvement's Specialized Register, MEDLINE, Embase, PsycINFO and a number of other sources on 20 May 2017

Cochrane2018

11. Pharmacological interventions for apathy in Alzheimer's disease.

Pharmacological interventions for apathy in Alzheimer's disease. BACKGROUND: Despite the high prevalence of apathy in Alzheimer's disease (AD), and its harmful effects, there are currently no therapies proven to treat this symptom. Recently, a number of pharmacological therapies have been investigated as potential treatments for apathy in AD. OBJECTIVES: Objective 1: To assess the safety and efficacy of pharmacotherapies for the treatment of apathy in Alzheimer's disease (AD).Objective 2

Cochrane2018

12. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.

Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. BACKGROUND: Alzheimer's disease is characterized by the deposition of amyloid-beta (Aβ) plaques in the brain. Aβ is produced from the sequential cleavage of amyloid precursor protein by β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) followed by γ-secretase. Verubecestat is an oral BACE-1 inhibitor that reduces the Aβ level in the cerebrospinal fluid of patients with Alzheimer's disease. METHODS: We conducted (...) a randomized, double-blind, placebo-controlled, 78-week trial to evaluate verubecestat at doses of 12 mg and 40 mg per day, as compared with placebo, in patients who had a clinical diagnosis of mild-to-moderate Alzheimer's disease. The coprimary outcomes were the change from baseline to week 78 in the score on the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog; scores range from 0 to 70, with higher scores indicating worse dementia) and in the score on the Alzheimer's Disease

NEJM2018

13. Abnormal clotting of the intrinsic/contact pathway in Alzheimer disease patients is related to cognitive ability

Abnormal clotting of the intrinsic/contact pathway in Alzheimer disease patients is related to cognitive ability 29700007 2018 12 04 2473-9537 2 9 2018 05 08 Blood advances Blood Adv Abnormal clotting of the intrinsic/contact pathway in Alzheimer disease patients is related to cognitive ability. 954-963 10.1182/bloodadvances.2018017798 Alzheimer disease (AD) is a neurodegenerative disorder characterized by extracellular β-amyloid (Aβ) deposition. Although peripheral inflammation (...) 24821909 Am J Psychiatry. 2012 Mar;169(3):300-8 22193532 Acta Neuropathol. 2016 May;131(5):687-707 27038189 Brain. 2011 Feb;134(Pt 2):335-44 21257651 Jpn J Psychiatry Neurol. 1988 Dec;42(4):819-24 3249475 Neuron. 2010 Jun 10;66(5):695-709 20547128 J Neurosci Res. 2012 Dec;90(12):2247-58 22987781 Alzheimer Dis Assoc Disord. 1998 Jun;12(2):102-8 9651139 J Neurol Sci. 2009 Aug 15;283(1-2):17-20 19249797 Curr Gerontol Geriatr Res. 2013;2013:986254 24382959 Neuron. 2016 Jul 6;91(1):56-66 27292537 Arch

Blood advances2018 Full Text: Link to full Text with Trip Pro

14. Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive

Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive NIHR DC | Signal - Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Stopping Donepezil may be linked to nursing home placement for people with Alzheimer’s disease, but a “cause and effect” not conclusive (...) Published on 11 December 2015 This follow up study examined whether the drugs donepezil or memantine affected the chance that people with Alzheimer’s disease could continue to live in the community, rather than move permanently to a nursing home. One or both of the drugs was taken for a year and then participants could have any treatment thereafter. The study found that stopping donepezil doubled the risk of going into a nursing home up to a year afterwards, compared with continuing to take donepezil

NIHR Dissemination Centre2018

15. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer`s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study

Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer`s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study 29452684 2018 03 02 1474-4465 17 3 2018 Mar The Lancet. Neurology Lancet Neurol Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. 213-222 S1474-4422(18)30039-5 (...) 10.1016/S1474-4422(18)30039-5 Pimavanserin is a selective 5-HT 2A receptor inverse agonist and antagonist approved in the USA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. No safe or effective pharmacological treatment is approved for psychosis in patients with Alzheimer's disease. Therefore, we aimed to evaluate the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis. We did a phase 2

EvidenceUpdates2018

16. Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a primary care setting.

Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a primary care setting. BACKGROUND: Alzheimer's disease and other forms of dementia are becoming increasingly common with the aging of most populations. The majority of individuals with dementia will first present for care and assessment in primary care settings. There is a need for brief dementia screening instruments that can accurately diagnose dementia in primary care settings. The Mini-Cog is a brief (...) , cognitive screening test that is frequently used to evaluate cognition in older adults in various settings. OBJECTIVES: To determine the diagnostic accuracy of the Mini-Cog for diagnosing Alzheimer's disease dementia and related dementias in a primary care setting. SEARCH METHODS: We searched the Cochrane Dementia and Cognitive Improvement Register of Diagnostic Test Accuracy Studies, MEDLINE, Embase and four other databases, initially to September 2012. Since then, four updates to the search were

Cochrane2018

17. Can Exercise Improve Cognitive Symptoms of Alzheimer's Disease? A Meta-Analysis

Can Exercise Improve Cognitive Symptoms of Alzheimer's Disease? A Meta-Analysis 29363108 2018 01 24 1532-5415 2018 Jan 24 Journal of the American Geriatrics Society J Am Geriatr Soc Can Exercise Improve Cognitive Symptoms of Alzheimer's Disease? A Meta-Analysis. 10.1111/jgs.15241 To examine the effects of exercise training on cognitive function in individuals at risk of or diagnosed with Alzheimer's disease (AD). Meta-analysis. PubMed, Scopus, ClinicalTrials.gov, and ProQuest were searched from

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

18. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. BACKGROUND: Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid. METHODS: We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild (...) dementia due to Alzheimer's disease, defined as a Mini-Mental State Examination (MMSE) score of 20 to 26 (on a scale from 0 to 30, with higher scores indicating better cognition) and with amyloid deposition shown by means of florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid. Patients were randomly assigned to receive solanezumab at a dose of 400 mg or placebo intravenously every 4 weeks for 76 weeks. The primary outcome was the change from baseline to week 80

NEJM2018

19. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.

Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. Importance: New therapeutic approaches for Alzheimer disease (AD) are needed. Objective: To assess whether idalopirdine, a selective 5-hydroxytryptamine-6 receptor antagonist, is effective for symptomatic treatment of mild to moderate AD. Design, Setting, and Participants: Three randomized clinical trials that included 2525 patients aged 50 (...) studies: change in cognition total score (range, 0-70; a lower score indicates less impairment) from baseline to 24 weeks measured by the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog); key secondary end points: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change Scale and 23-item Activities of Daily Living Inventory scores. Dose group efficacy required a significant benefit over placebo for the primary end point and 1 or more key secondary end

JAMA2018 Full Text: Link to full Text with Trip Pro

20. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial

24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial 29097166 2017 12 08 2017 12 19 1474-4465 16 12 2017 Dec The Lancet. Neurology Lancet Neurol 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. 965-975 S1474-4422(17)30332-0 10.1016/S1474-4422(17)30332-0 Nutrition is an important (...) modifiable risk factor in Alzheimer's disease. Previous trials of the multinutrient Fortasyn Connect showed benefits in mild Alzheimer's disease dementia. LipiDiDiet investigated the effects of Fortasyn Connect on cognition and related measures in prodromal Alzheimer's disease. Here, we report the 24-month results of the trial. LipiDiDiet was a 24-month randomised, controlled, double-blind, parallel-group, multicentre trial (11 sites in Finland, Germany, the Netherlands, and Sweden), with optional 12

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro